BRCA2 and triple-negative breast carcinoma: In fact, some studies using specific knockdown of PARPs showed that only the knockdown of PARP-1, but not PARP-2, replicates: (i) the synthetic lethal effect of PARPi on BRCA2 mutant cells (3); (ii) potentiation of cisplatin by PARPi in BRCA-proficient triple negative breast cancer cells (34); and (iii) sensitization of melanoma cells in vitro to temozolomide (35).